Shaping the Future of Personalized Medicine
Information and Networking Platform
This information and networking platform addresses all players in the
field of personalized medicine, biomarker development, and (companion)
diagnostics. If you would like to further develop your
(companion) diagnostics or biomarkers and need access to patient data and human
sample material, then take part in our Codex4SMEs network and events. Here you will find experts and
representatives of biobanks who will inform you about access to
sample material and further development of products for personalized medicine.
Take advantage of the opportunity to interview experts in one-on-one
discussions and advice for prospects in future diagnostics.
For whom?
SMEs, pharma companies, manufacturers, service providers, research teams, clinicians, cluster organisations active in the area of Personalized Medicine, focused on:
- (Companion) Diagnostics
- Lab-on-a-chip
- In Vitro Diagnostics
- Artificial Intelligence & Imaging
- Wearables
- Bioinformatics
- eHealth
- Financing & Investments
- And all who are interested in improving personalized medicine
Why participate?
- As Entreprise - find qualified European experts and collaboration partners during effective one-to-one meetings
- As Research & Technology Organisation - find European partners for technology transfer
- As Product Developer - find partners to discuss new technology and innovative solutions
About Codex4SMEs project
The Interreg Codex4SMEs project plans to improve healthcare by the enhanced adoption of personalized medicine in North-West Europe and beyond. The objective is to establish a network, which supports SMEs along the whole value chain of Companion diagnostics (Cdx) development.
Within this network companies get access to biobank samples, knowledge transfer service of biomarker/biobanking, transnational roadshows to venture and large companies, business model and expert access for business growth and scaling as well as tailored support dependent form the product TRL levels of the SMEs.
